D.E. Shaw & Co’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.4M Sell
193,483
-237,645
-55% -$44.1M 0.02% 860
2025
Q4
$86M Sell
431,128
-528,409
-55% -$95.8M 0.05% 456
2025
Q3
$150M Buy
959,537
+352,518
+58% +$56M 0.08% 273
2025
Q2
$92.1M Buy
+607,019
New +$80.9M 0.07% 352
2025
Q1
Sell
-84,656
Closed -$14.2M 4333
2024
Q4
$15.6M Buy
+84,656
New +$16.3M 0.01% 1195
2024
Q1
Sell
-4,857
Closed -$1.15M 4400
2023
Q4
$1.15M Buy
4,857
+3,737
+334% +$735K ﹤0.01% 3050
2023
Q3
$219K Buy
+1,120
New +$230K ﹤0.01% 3728
2023
Q2
Sell
-12,022
Closed -$2.43M 4285
2023
Q1
$2.43M Sell
12,022
-22,687
-65% -$5.14M ﹤0.01% 2540
2022
Q4
$7.56M Sell
34,709
-66,323
-66% -$14.5M 0.01% 1697
2022
Q3
$19.9M Sell
101,032
-66,438
-40% -$14.3M 0.02% 851
2022
Q2
$35.8M Buy
167,470
+59,310
+55% +$14.5M 0.04% 549
2022
Q1
$30.7M Buy
108,160
+107,148
+10,588% +$33M 0.03% 741
2021
Q4
$381K Sell
1,012
-1,815
-64% -$705K ﹤0.01% 4553
2021
Q3
$1.17M Buy
2,827
+1,985
+236% +$824K ﹤0.01% 3483
2021
Q2
$311K Buy
+842
New +$281K ﹤0.01% 4256
2021
Q1
Sell
-15,306
Closed -$3.82M 4109
2020
Q4
$3.82M Sell
15,306
-7,309
-32% -$1.74M ﹤0.01% 2080
2020
Q3
$5.12M Sell
22,615
-12,936
-36% -$2.68M 0.01% 1669
2020
Q2
$6.2M Sell
35,551
-20,693
-37% -$3.3M 0.01% 1501
2020
Q1
$7.1M Buy
56,244
+13,934
+33% +$2.09M 0.01% 1205
2019
Q4
$6.46M Sell
42,310
-49,817
-54% -$6.9M 0.01% 1530
2019
Q3
$12.2M Buy
92,127
+27,430
+42% +$3.68M 0.02% 1048
2019
Q2
$9.18M Sell
64,697
-52,401
-45% -$7.11M 0.01% 1185
2019
Q1
$17M Buy
117,098
+16,011
+16% +$2.1M 0.02% 805
2018
Q4
$11.4M Sell
101,087
-119,307
-54% -$14.9M 0.02% 1006
2018
Q3
$29.7M Buy
220,394
+63,322
+40% +$7.82M 0.04% 599
2018
Q2
$17.6M Buy
157,072
+25,154
+19% +$2.72M 0.02% 780
2018
Q1
$14.1M Sell
131,918
-288,049
-69% -$31M 0.02% 817
2017
Q4
$46M Sell
419,967
-221,707
-35% -$24.1M 0.06% 371
2017
Q3
$69.3M Buy
641,674
+107,447
+20% +$11M 0.11% 233
2017
Q2
$54M Sell
534,227
-26,564
-5% -$2.45M 0.09% 279
2017
Q1
$50.4M Sell
560,791
-106,507
-16% -$9.05M 0.09% 284
2016
Q4
$50.8M Buy
667,298
+266,559
+67% +$20.2M 0.09% 291
2016
Q3
$33.4M Buy
400,739
+112,265
+39% +$9.41M 0.06% 412
2016
Q2
$23.8M Buy
288,474
+103,746
+56% +$8.55M 0.04% 485
2016
Q1
$14M Sell
184,728
-52,091
-22% -$3.86M 0.03% 683
2015
Q4
$19M Buy
236,819
+138,774
+142% +$10M 0.03% 654
2015
Q3
$6.23M Buy
98,045
+5,014
+5% +$360K 0.01% 1243
2015
Q2
$6.54M Sell
93,031
-86,655
-48% -$6.41M 0.01% 1286
2015
Q1
$14.2M Buy
179,686
+74,514
+71% +$5.5M 0.02% 767
2014
Q4
$6.69M Sell
105,172
-144,227
-58% -$9.04M 0.01% 1359
2014
Q3
$14.9M Sell
249,399
-82,799
-25% -$4.74M 0.02% 857
2014
Q2
$17.8M Buy
332,198
+174,945
+111% +$9.6M 0.02% 757
2014
Q1
$9.49M Sell
157,253
-31,784
-17% -$1.85M 0.01% 1084
2013
Q4
$10M Sell
189,037
-168,620
-47% -$8.47M 0.01% 1138
2013
Q3
$16.5M Buy
357,657
+156,580
+78% +$7.19M 0.03% 684
2013
Q2
$8.25M Buy
+201,077
New +$8.62M 0.02% 997

Other funds holding CRL

D.E. Shaw & Co's CRL Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Charles River Laboratories (CRL) stake by 55% in Q1 2026, selling an estimated $44.1M and leaving 193,483 shares worth $33.4M. The position accounts for 0.02% of the portfolio, ranked #860.

D.E. Shaw & Co first reported a position in CRL in Q2 2013 and has held it in 46 quarters since. The position peaked at $150M in Q3 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • D.E. Shaw & Co held 193,483 shares of Charles River Laboratories worth $33.4M as of Q1 2026.
  • D.E. Shaw & Co sold 237,645 Charles River Laboratories shares in Q1 2026, an estimated $44.1M.
  • Charles River Laboratories made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #860 holding.
  • D.E. Shaw & Co first reported a position in Charles River Laboratories in Q2 2013 and has held it in 46 quarters since.
  • D.E. Shaw & Co's Charles River Laboratories position peaked at $150M in Q3 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.